Good Laboratory Practices (GLPs)

Slides:



Advertisements
Similar presentations
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Advertisements

Tips to a Successful Monitoring Visit
PRINCIPLES OF A CALIBRATION MANAGEMENT SYSTEM
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Clinical QA Data Audits A GCP Point of View Linda Del Paggio GCP Compliance BioBridges, LLC.
1 Everything You Wanted to Know About GLPs…. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI.
Establish Verification Procedures (Task 11 / Principle 6)
Public and Private Interests in Animal Research LAT Chapter 1.
25 TAC Quality Assurance in a licensed ASC
Laboratory Personnel Dr/Ehsan Moahmen Rizk.
John Naim, PhD Director Clinical Trials Research Unit
All You Never Wanted to Know About GLP and GMP
QC/QA Mary Malarkey Director, Division of Case Management Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research March.
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
A Review of the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals Created by Marc S. Hulin, DVM, Dipl. ACLAM.
Standard Operating Procedures.  To understand: › The purpose of having SOP’s and how they affect the daily workings of laboratories.  To discuss: ›
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
CLIA COMPLIANCE. What is CLIA? In 1988 Congress turned its attention to deficiencies in the quality of services provided by the nation’s laboratories.
Seafood HACCP Alliance for Training and Education Chapter 10 Principle 6: Establish Verification Procedures.
Overview of Good Clinical Practices (GCPs)
World Health Organization
Good Laboratory Practice
Regulatory Overview.
Quality Assurance in Bio-availability / Bio-equivalence studies. DR
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
Good Manufacturing Practices
Carolyn Hommel Good Clinical Practice Program FDA February 25, 2004
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
MB RESEARCH LABORATORIES Increased Regulatory Vigilance with respect to GLP Test Article Characterization George L. DeGeorge, Ph.D., DABT MB Research Laboratories.
Good Laboratory Practice CFR 21 Part 58 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International
3rd Dimension of Product Translation: Industrialization
Investigational New Drug Application (IND)
Presented by Steven P. Feltman Food Safety and Quality Specialist.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Lecture Topic 4: Good Manufacturing Practices (GMPs)
PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?
Read the SMALL PRINT of the 1572 The Essential GCP Document.
Important informations
GLP Training Daniel W. Sved, PhD Lori A. Rush, BS, LAT, RQAP-GLP
Regulatory Issues in Laboratory Managment
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
1 Denise K. Thwing, MAS, RN, CCRA March 31, 2010 Version: Final 31-Mar-2010.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
QSR and GLP What exactly are these?.
Overview of FDA's Regulatory Framework for PET Drugs
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.
Office of Human Research Protection Georgia Health Sciences University.
Regulatory Issues in Laboratory Management
UNIT-II CLINICAL DATA. UNIT-II CLINICAL DATA: Clinical Data, Application, Challenges, Solutions, Clinical Data Management System.
Standard Operating Procedures §
Pharmaceutical Quality Control & current Good Manufacturing Practice
Most Common Deficiencies Cheryl O. Morton Managing Director, AIHA Laboratory Accreditation Programs, LLC.
E-Clinical
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
Good Laboratory Practice
Responsibilities of Test Facility Management, Study Director, Principal Investigator and Study Personnel G. Jacobs Belgian GLP Monitorate Zagreb, 17 December.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Responsibilities of Sponsor, Investigator and Monitor
נמטוציטים משושנת ים Eli. S Lec. No.2.
Pharmaceutical Quality Control & current Good Manufacturing Practice
Clinical Engineering Lecture (3).
Good Laboratory Practices
Good Laboratory Practice CFR 21 Part 58
Presentation transcript:

Good Laboratory Practices (GLPs) Created by Marc S. Hulin, DVM, Dipl. ACLAM

History Until the mid 1970’s the Food and Drug Administration (FDA) assumed that reports being submitted in support of new drug or medical device applications were accurate and truthful Two submissions aroused suspicion and resulted in “for cause” inspections of sponsor laboratory

History “For cause” means an inspection initiated by FDA when there is reason to suspect a problem in a regulated product. Results presented to Congress: experiments poorly conceived, executed or inaccurately analyzed technical personnel unaware of importance of SOPs, accurate record keeping, observations, and compound administration

History Management did not assure critical review of data or proper personnel supervision Scientific qualification and adequate personnel training were lacking Disregard for need to observe proper lab, animal care, and data mngmt. Procedures Sponsors failed to monitor contract testing labs Failure to verify accuracy and completeness of scientific data

History FDA’s responsibility and authority for GLPs is derived from the Federal Food, Drug, and Cosmetic Act of 1985.

GLP Coverage Purpose of GLPs: assure the quality & integrity of data submitted to FDA in support of the safety of regulated products GLPs have heavy emphasis on data recording, record & specimen retention Requires each study to have a study director Study director: ultimate responsibility for implementation of the protocol & conduct of the study

GLP Coverage Covers all nonclinical laboratory studies Food & color additive petitions, NDA & NADA Toxicity studies (in vitro & in vivo) Excluded: human subject trials, clinical or field trials in animals, basic exploratory studies

Definitions Sponsor: person who initiates & supports nonclinical laboratory study, a person who submits nonclinical study to FDA or testing facility that initiates & conducts the study Testing facility: person who actually conducts a nonclinical laboratory study Test system: any animal, plant, or microorganism to which test or control article is administered

Definitions Specimen: any material derived from a test system for examination or analysis Raw data: any laboratory work sheets, records, memoranda, notes or copies that are result of original observations Quality assurance unit: monitor study conduct Study director: individual responsible for the overall conduct of a nonclinical laboratory study

Quality Assurance Unit (QAU) QAU records are exempt from routine FDA inspections Maintain a copy of master schedule sheet of all nonclinical laboratory studies Inspect each study at intervals adequate to assure the integrity of the study

Quality Assurance Unit (QAU) Determine that no deviations from approved protocols or SOPs were made without proper authorization & documentation Review the final study report to assure methods & SOPs reflect raw data

Maintenance & Calibration of Equipment Equipment shall be adequately inspected, cleaned & maintained Equipment used for assessment of data shall be tested, calibrated and/or standardized Scales & balances should be calibrated at regular intervals (usually ranging from 1-12 months)

Standard Operating Procedures (SOPs) Testing facility shall have SOPs adequate to insure the quality & integrity of the data generated in the course of a study all deviations from SOPs shall be authorized by the study director & documented in the raw data

Animal Care SOPs are required for all aspects of animal care Newly received animals shall be isolated & health status evaluated Animals shall be free of any disease or condition that might interfere at beginning of study

Animal Care Animals of different species shall be housed in separate rooms Feed & water analyzed periodically for contaminants Contaminant analysis of food & water for each & every study is not a requirement nor is analysis for laundry list of contaminants